June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation
Author Affiliations & Notes
  • Karen Tubridy
    Eleven Biotherapeutics, Cambridge, MA
  • Michael H Goldstein
    Eleven Biotherapeutics, Cambridge, MA
    Ophthalmology, Tufts Medical Center, Boston, MA
  • Jennifer Agahigian
    Eleven Biotherapeutics, Cambridge, MA
  • Marianne Magill
    Eleven Biotherapeutics, Cambridge, MA
  • Joseph Kovalchin
    Eleven Biotherapeutics, Cambridge, MA
  • Eric S Furfine
    Eleven Biotherapeutics, Cambridge, MA
  • Abbie Celniker
    Eleven Biotherapeutics, Cambridge, MA
  • Footnotes
    Commercial Relationships Karen Tubridy, Eleven Bio (E), Eleven Bio (I); Michael Goldstein, Eleven bio (E), Eleven Bio (I); Jennifer Agahigian, Eleven Bio (E), Eleven Bio (I); Marianne Magill, Eleven Bio (C); Joseph Kovalchin, Eleven Bio (E), Eleven Bio (I); Eric Furfine, eleven bio (E), eleven bio (I); Abbie Celniker, Eleven Bio (E), Eleven Bio (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4488. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Karen Tubridy, Michael H Goldstein, Jennifer Agahigian, Marianne Magill, Joseph Kovalchin, Eric S Furfine, Abbie Celniker; Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4488.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Interleukin-1 (IL-1) is a key mediator of ocular surface inflammation in dry eye disease (DED) and allergic conjunctivitis (AC). IL-1 is important not only in the initiation and maintenance of the inflammatory response, but also in mediating hypersensitization of peripheral nerves. EBI-005 is an IL-1 receptor inhibitor specifically designed and engineered for topical ophthalmic delivery. EBI-005 has been evaluated in several randomized, controlled clinical trials in DED and AC.

Methods: In a phase 1 healthy volunteer study, 16 subjects were randomized to topical EBI-005 (two different doses) or vehicle control 3x/day for one day. In a double-masked, placebo-controlled phase 2 study, 74 subjects with moderate to severe DED were randomized to receive vehicle or EBI-005 (5 mg/mL or 20 mg/mL) 3x/day for six weeks. In an exploratory, phase 2 study, 159 subjects with moderate to severe AC were randomized to EBI-005 or vehicle control and assigned to one of two different models of AC. Most recently, in a double-masked, placebo-controlled phase 3 study in subjects with moderate to severe DED, 669 subjects were randomized to receive vehicle or EBI-005 5 mg/mL 3x/day for 12 weeks. Safety, biological activity and immunogenicity were assessed.

Results: Topical EBI-005 was generally safe and well tolerated in all studies. No drug specific antibodies have been detected to date. There were no treatment related serious ocular or non-ocular adverse events. In the phase 2 DED study, EBI-005 significantly improved signs and symptoms of DED compared to baseline at week six by up to 30% (p<0.001) and 36% (p<0.001) respectively. In the phase 2 AC study, EBI-005 showed statistically significant (p<0.05), clinically meaningful (>25%) improvement in symptoms of AC including ocular itching, ocular tearing and total nasal symptoms at multiple time points compared to vehicle.

Conclusions: Topical EBI-005 treatment is a promising new therapy for patients with moderate to severe dry eye disease and late phase allergic conjunctivitis. These results further validate the importance of IL-1 blockade in DED and AC. They support continued development of topical EBI-005 in these indications to further characterize the safety and efficacy of the drug in patients with ocular surface inflammation.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×